PharmiWeb.com - Global Pharma News & Resources
27-Feb-2019

Cholangiocarcinoma Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

LAS VEGAS, Feb. 27, 2019 /PRNewswire/ -- Prevalent population of Cholangiocarcinoma (CCA) is increasing at a CAGR of 1.5% for the study period of 2017-2028

The higher incidence of Cholangiocarcinoma (CCA) in the United States was 6,768 cases in 2017

1. Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom. On the other hand, Spain had the lowest incident population.

2. Cholangiocarcinoma incident cases of Japan were 4,287 in 2017, increasing at a CAGR of 0.5% for the study period of 2017-2028.

3. Cholangiocarcinoma total prevalent population was estimated to be 18,470 in 7MM

(Albany, US) DelveInsight launched Cholangiocarcinoma (CCA) or Bile Duct Cancer - Market Insights, Epidemiology and Market Forecast- 2028

Key topics covered

1. The Cholangiocarcinoma market report covers a descriptive overview and comprehensive insight of the Cholangiocarcinoma epidemiology in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.

2. The Cholangiocarcinoma market report includes both the current and emerging therapies.

3. The Cholangiocarcinoma market report includes global historical and forecasted market covering drug outreach in 7 MM.

4. The Cholangiocarcinoma market report provides an edge while developing business strategies, by understanding trends shaping and driving the Cholangiocarcinoma market.

Request a sample page : https://www.delveinsight.com/dev-sample.php?form_name=Cholangiocarcinoma-(CCA)--Market-Insights,-Epidemiology-and-Market-Forecast---2028https://www.delveinsight.com/dev-sample.php?form_name=Cholangiocarcinoma-(CCA)--Market-Insights,-Epidemiology-and-Market-Forecast---2028

"Males are more prone to Cholangiocarcinoma than females among all countries. Cholangiocarcinoma overall incidence in both the genders is subjected to increase in the coming years"

Currently, Cholangiocarcinoma or Bile Duct Cancer market size for early stage majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy the following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.

The improvements in molecular understanding have identified multiple actionable mutations, leading to the development of targeted therapies with promising results in early clinical trials. In the near future, a personalized treatment approach, targeting FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years by optimizing the outcomes of patients with this aggressive malignancy. Ongoing advances in this arena with distinct subtypes of Bile Duct Cancer would expedited bench-to beside translational investigation of new actionable mutations and targeted agents.

Bile Duct Cancer market size in the 7 MM is found to be USD 379.57 million in 2017, growing at a CAGR of 12.3% for the study period (2017-2028). The treatment strategy, as well as market share, will transform in the near future with the advent of targeted therapies. In the United States, it accounts for the highest market size of USD 146.12 million in 2017. In EU5, the Cholangiocarcinoma market size in Germany was found to be highest with USD 82.46 million in 2017, whereas Spain has the lowest share with USD 3.69 million in 2017. However, Bile Duct Cancer market size in Japan was found to be USD 96.73 million in 2017, growing at a CAGR of 9.7% during the forecast period.

Do you want a free Cholangiocarcinoma Market Report demo? If yes click here.

The market is focusing on to provide better treatment options for Cholangiocarcinoma with the continuous efforts in research and development, with the involvement of key players like

1. Agios Pharmaceuticals

2. Bayer

3. Basilea Pharmaceutica

4. Delcath Systems

5. Hoffmann-La Roche

6. Incyte Corporation

and many others.

Drugs that are involved are

1. AG-120

2. Pemigatinib

3. Infigratinib

4. Regorafenib

5. LOXO-101

6. Entrectinib

And many others

Click here to get a free sample page: https://www.delveinsight.com/dev-sample.php?form_name=Cholangiocarcinoma-(CCA)--Market-Insights,-Epidemiology-and-Market-Forecast---2028https://www.delveinsight.com/dev-sample.php?form_name=Cholangiocarcinoma-(CCA)--Market-Insights,-Epidemiology-and-Market-Forecast---2028

Table of contents

1. Key Insights

2. Cholangiocarcinoma (Bile Duct Cancer) Market Overview at a Glance

3. Cholangiocarcinoma (Bile Duct Cancer) Disease Background and Overview

4. Cholangiocarcinoma (Bile Duct Cancer) Epidemiology and Patient Population

5. Cholangiocarcinoma (Bile Duct Cancer) Total Diagnosed Incident Cases in 7MM

6. Cholangiocarcinoma (Bile Duct Cancer) United States Epidemiology

7. Cholangiocarcinoma (Bile Duct Cancer) EU5 Epidemiology

7.1. Cholangiocarcinoma (Bile Duct Cancer) Germany Epidemiology

7.2. Cholangiocarcinoma (Bile Duct Cancer)  France Epidemiology

7.3. Cholangiocarcinoma (Bile Duct Cancer) Italy Epidemiology

7.4. Cholangiocarcinoma (Bile Duct Cancer) Spain Epidemiology

7.5. Cholangiocarcinoma (Bile Duct Cancer) United Kingdom Epidemiology

8. Cholangiocarcinoma (Bile Duct Cancer) Japan Epidemiology

9. Cholangiocarcinoma (Bile Duct Cancer) Therapies and Treatment strategies

10. Unmet Needs

11. Cholangiocarcinoma (Bile Duct Cancer)  Emerging Therapies

11.1. Key Cross Competition

11.2. Ivosidenib: Agios Pharmaceuticals

11.3. Pemigatinib: Incyte Corporation

11.4. Infigratinib: QED Therapeutics

11.5. Melphalan: Delcath Systems

11.6.Derazantinib: Basilea Pharmaceutica

11.7. Regorafenib: Bayer

11.8. Larotrectinib: Loxo Oncology/ Bayer

11.9. Entrectinib: Roche

11.10. Erdafitinib: Janssen Pharmaceutical

12. Cholangiocarcinoma (Bile Duct Cancer) 7MM Market Analysis

13. United States: Market Outlook

14. EU-5 countries: Market Outlook

14.1. Germany Market Size

14.2. France Market Size

14.3. Italy Market Size

14.4. Spain Market Size

14.5. United Kingdom Market Size

16. Market Drivers

17. Market Barriers

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur
info@delveinsight.com
+919650213330

 

 

Editor Details

Last Updated: 27-Feb-2019